127 related articles for article (PubMed ID: 37417165)
1. Epitope prediction and designing of receptor inhibitor of Dengue Envelope Protein: An
Uttam G; Kumari A; Singh K
J Vector Borne Dis; 2023; 60(2):161-171. PubMed ID: 37417165
[TBL] [Abstract][Full Text] [Related]
2. Mapping the Human Memory B Cell and Serum Neutralizing Antibody Responses to Dengue Virus Serotype 4 Infection and Vaccination.
Nivarthi UK; Kose N; Sapparapu G; Widman D; Gallichotte E; Pfaff JM; Doranz BJ; Weiskopf D; Sette A; Durbin AP; Whitehead SS; Baric R; Crowe JE; de Silva AM
J Virol; 2017 Mar; 91(5):. PubMed ID: 28031369
[TBL] [Abstract][Full Text] [Related]
3. Epitopes based drug design for dengue virus envelope protein: A computational approach.
Wadood A; Mehmood A; Khan H; Ilyas M; Ahmad A; Alarjah M; Abu-Izneid T
Comput Biol Chem; 2017 Dec; 71():152-160. PubMed ID: 29096381
[TBL] [Abstract][Full Text] [Related]
4. Virus-like particles derived from Pichia pastoris-expressed dengue virus type 1 glycoprotein elicit homotypic virus-neutralizing envelope domain III-directed antibodies.
Poddar A; Ramasamy V; Shukla R; Rajpoot RK; Arora U; Jain SK; Swaminathan S; Khanna N
BMC Biotechnol; 2016 Jun; 16(1):50. PubMed ID: 27301568
[TBL] [Abstract][Full Text] [Related]
5. Dengue virus-like particles mimic the antigenic properties of the infectious dengue virus envelope.
Metz SW; Thomas A; White L; Stoops M; Corten M; Hannemann H; de Silva AM
Virol J; 2018 Apr; 15(1):60. PubMed ID: 29609659
[TBL] [Abstract][Full Text] [Related]
6. A new quaternary structure epitope on dengue virus serotype 2 is the target of durable type-specific neutralizing antibodies.
Gallichotte EN; Widman DG; Yount BL; Wahala WM; Durbin A; Whitehead S; Sariol CA; Crowe JE; de Silva AM; Baric RS
mBio; 2015 Oct; 6(5):e01461-15. PubMed ID: 26463165
[TBL] [Abstract][Full Text] [Related]
7.
Panchal R; Bapat S; Mukherjee S; Chowdhary A
Indian J Pharmacol; 2021; 53(6):471-479. PubMed ID: 34975135
[TBL] [Abstract][Full Text] [Related]
8. Dimerization of Dengue Virus E Subunits Impacts Antibody Function and Domain Focus.
Thomas A; Thiono DJ; Kudlacek ST; Forsberg J; Premkumar L; Tian S; Kuhlman B; de Silva AM; Metz SW
J Virol; 2020 Aug; 94(18):. PubMed ID: 32611757
[TBL] [Abstract][Full Text] [Related]
9. Dengue virus neutralization by human immune sera: role of envelope protein domain III-reactive antibody.
Wahala WM; Kraus AA; Haymore LB; Accavitti-Loper MA; de Silva AM
Virology; 2009 Sep; 392(1):103-13. PubMed ID: 19631955
[TBL] [Abstract][Full Text] [Related]
10. Natural immunogenic properties of bioinformatically predicted linear B-cell epitopes of dengue envelope and pre-membrane proteins.
Nadugala MN; Jeewandara C; Jadi RS; Malavige GN; de Silva AM; Premaratne PH; Goonasekara CL
BMC Immunol; 2021 Nov; 22(1):71. PubMed ID: 34732126
[TBL] [Abstract][Full Text] [Related]
11. [Mapping of the B Cell Neutralizing Epitopes on ED III of Envelope Protein from Dengue Virus].
Lin Y; Wen K; Guo Y; Qiu L; Pan Y; Yu L; Di B; Chen Y
Bing Du Xue Bao; 2015 Nov; 31(6):665-73. PubMed ID: 26951013
[TBL] [Abstract][Full Text] [Related]
12. A tetravalent virus-like particle vaccine designed to display domain III of dengue envelope proteins induces multi-serotype neutralizing antibodies in mice and macaques which confer protection against antibody dependent enhancement in AG129 mice.
Ramasamy V; Arora U; Shukla R; Poddar A; Shanmugam RK; White LJ; Mattocks MM; Raut R; Perween A; Tyagi P; de Silva AM; Bhaumik SK; Kaja MK; Villinger F; Ahmed R; Johnston RE; Swaminathan S; Khanna N
PLoS Negl Trop Dis; 2018 Jan; 12(1):e0006191. PubMed ID: 29309412
[TBL] [Abstract][Full Text] [Related]
13. Identification and characterization of a linearized B-cell epitope on the pr protein of dengue virus.
Song KY; Zhao H; Li SH; Li XF; Deng YQ; Wang HJ; Ye Q; Zhu SY; Jiang ZY; Zhang FC; Qin ED; Qin CF
J Gen Virol; 2013 Jul; 94(Pt 7):1510-1516. PubMed ID: 23559476
[TBL] [Abstract][Full Text] [Related]
14. Immunodomination of Serotype-Specific CD4+ T-Cell Epitopes Contributed to the Biased Immune Responses Induced by a Tetravalent Measles-Vectored Dengue Vaccine.
Lin TH; Chen HW; Hsiao YJ; Yan JY; Chiang CY; Chen MY; Hu HM; Wu SH; Pan CH
Front Immunol; 2020; 11():546. PubMed ID: 32300346
[TBL] [Abstract][Full Text] [Related]
15. Immunodominance changes as a function of the infecting dengue virus serotype and primary versus secondary infection.
Weiskopf D; Angelo MA; Sidney J; Peters B; Shresta S; Sette A
J Virol; 2014 Oct; 88(19):11383-94. PubMed ID: 25056881
[TBL] [Abstract][Full Text] [Related]
16. The human antibody response to dengue virus infection.
Wahala WM; Silva AM
Viruses; 2011 Dec; 3(12):2374-95. PubMed ID: 22355444
[TBL] [Abstract][Full Text] [Related]
17. Recombinant Protein Mimicking the Antigenic Structure of the Viral Surface Envelope Protein Reinforces Induction of an Antigen-Specific and Virus-Neutralizing Immune Response Against Dengue Virus.
Kim J; Lim TY; Park J; Jang YS
J Microbiol; 2023 Jan; 61(1):131-143. PubMed ID: 36723792
[TBL] [Abstract][Full Text] [Related]
18. Identification of highly conserved, serotype-specific dengue virus sequences: implications for vaccine design.
Chong LC; Khan AM
BMC Genomics; 2019 Dec; 20(Suppl 9):921. PubMed ID: 31874646
[TBL] [Abstract][Full Text] [Related]
19. Universal Dengue Vaccine Elicits Neutralizing Antibodies against Strains from All Four Dengue Virus Serotypes.
Uno N; Ross TM
J Virol; 2021 Jan; 95(4):. PubMed ID: 33208445
[TBL] [Abstract][Full Text] [Related]
20. Potent Neutralizing Human Monoclonal Antibodies Preferentially Target Mature Dengue Virus Particles: Implication for Novel Strategy for Dengue Vaccine.
Tsai WY; Chen HL; Tsai JJ; Dejnirattisai W; Jumnainsong A; Mongkolsapaya J; Screaton G; Crowe JE; Wang WK
J Virol; 2018 Dec; 92(23):. PubMed ID: 30185598
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
